Browsing by Subject "Quality of health care"

Now showing 1 - 7 of 7
  • Thumbnail Image
    Item
    Agile Innovation to transform healthcare: innovating in complex adaptive systems is an everyday process, not a light bulb event
    (BMJ, 2021) Holden, Richard J.; Boustani, Malaz A.; Azar, Jose; Medicine, School of Medicine
    Innovation is essential to transform healthcare delivery systems, but in complex adaptive systems innovation is more than ‘light bulb events’ of inspired creativity. To achieve true innovation, organisations must adopt a disciplined, customer-centred process. We developed the process of Agile Innovation as an approach any complex adaptive organisation can adopt to achieve rapid, systematic, customer-centred development and testing of innovative interventions. Agile Innovation incorporates insights from design thinking, Agile project management, and complexity and behavioural sciences. It was refined through experiments in diverse healthcare organisations. The eight steps of Agile Innovation are: (1) confirm demand; (2) study the problem; (3) scan for solutions; (4) plan for evaluation and termination; (5) ideate and select; (6) run innovation development sprints; (7) validate solutions; and (8) package for launch. In addition to describing each of these steps, we discuss examples of and challenges to using Agile Innovation. We contend that once Agile Innovation is mastered, healthcare delivery organisations can habituate it as the go-to approach to projects, thus incorporating innovation into how things are done, rather than treating innovation as a light bulb event.
  • Thumbnail Image
    Item
    Altered standards of care for health care providers in the pandemic influenza
    (Indiana University, 2009) Kinney, Eleanor D.; McCabe, Heather A.; Gilbert, Amy Lewis; Shisler, Janna Jo
    Pandemic influenza will pose tremendous challenges to health care providers, state public health authorities, and the public. All will have to conduct business under the most adverse of circumstances. It will be difficult for providers to meet the customary legal standards of care imposed by state and federal regulatory authorities, as well as the common law tort system. This white paper will explore the legal issues associated with altered standards of care in pandemic influenza.
  • Thumbnail Image
    Item
    COVID-19 Among African Americans: An Action Plan for Mitigating Disparities
    (American Public Health Association, 2021-02) Peek, Monica E.; Simons, Russell A.; Parker, William F.; Ansell, David A.; Rogers, Selwyn O.; Tucker Edmonds, Brownsyne; Obstetrics and Gynecology, School of Medicine
    As the COVID-19 pandemic has unfolded across the United States, troubling disparities in mortality have emerged between different racial groups, particularly African Americans and Whites. Media reports, a growing body of COVID-19-related literature, and long-standing knowledge of structural racism and its myriad effects on the African American community provide important lenses for understanding and addressing these disparities.However, troubling gaps in knowledge remain, as does a need to act. Using the best available evidence, we present risk- and place-based recommendations for how to effectively address these disparities in the areas of data collection, COVID-19 exposure and testing, health systems collaboration, human capital repurposing, and scarce resource allocation.Our recommendations are supported by an analysis of relevant bioethical principles and public health practices. Additionally, we provide information on the efforts of Chicago, Illinois' mayoral Racial Equity Rapid Response Team to reduce these disparities in a major urban US setting.
  • Thumbnail Image
    Item
    Insurance Denials of Care Amount to Unlicensed Medical Practice
    (Academy of Managed Care Pharmacy, 2020) Bennett, William E.; Pediatrics, School of Medicine
  • Thumbnail Image
    Item
    Pneumonia Management in Nursing Homes: Findings from a CMS Demonstration Project
    (Springer, 2021) Carnahan, Jennifer L.; Shearn, Andrew J.; Lieb, Kristi M.; Unroe, Kathleen T.; Medicine, School of Medicine
  • Thumbnail Image
    Item
    Towards quality adolescent-friendly services in TB care
    (Ingenta, 2021-07-01) Laycock, K.M.; Eby, J.; Arscott-Mills, T.; Argabright, S.; Caiphus, C.; Kgwaadira, B.; Lowenthal, E.D.; Steenhoff, A.P.; Enane, L.A.; Pediatrics, School of Medicine
  • Thumbnail Image
    Item
    Use of SGLT2 Inhibitors Reduces Heart Failure and Hospitalization: A Multicenter, Real-World Evidence Study
    (Kaiser Permanente, 2023) Blanco, Christopher Antonio; Garcia, Kara; Singson, Adrian; Smith, William R.; Medicine, School of Medicine
    Background: New research has produced evidence to support the use of diabetic drugs to prevent heart failure (HF). However, evidence of their effect in real-world clinical practice is limited. Objective: The objective of this study is to establish whether real-world evidence supports clinical trial findings that use of sodium-glucose cotransporter-2 inhibitor (SGLT2i) reduces rate of hospitalization and incidence of HF for patients with cardiovascular disease and type 2 diabetes. Methods: This retrospective study used electronic medical records to compare rate of hospitalization and incidence of HF among 37,231 patients with cardiovascular disease and type 2 diabetes under treatment with SGLT2i, glucagon-like peptide-1 receptor agonist (GLP1-RA), both, or neither. Results: Significant differences were found between medication class prescribed and number of hospitalizations (p < 0.0001) and incidence of HF (p < 0.0001). Post-hoc tests revealed reduced incidence of HF in the group treated with SGLT2i relative to GLP1-RA alone (p = 0.004) or neither of these key drugs (p < 0.001). No significant differences were observed between the group receiving both drug classes compared to SGLT2i alone. Discussion: Results of this real-world analysis are consistent with clinical trial findings that SGLT2i therapy reduces incidence of HF. The findings also suggest the need for further points of research in demographic and socioeconomic status differences. Conclusion: Real-world evidence supports clinical trial findings of SGLT2i reducing both incidence of HF and rate of hospitalization.